Facts from IQVIA

Copyright © 2019 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.

M02 2019

Facts from IQVIA

1

Indicator RUB USD EUR PACKS

Value M02/YTD'19, Bln. 179 2,7 2,4 0,8

Growth M02/YTD'19% 20% 2,5% 10% 3,7%

Market grew by 20% in value and by 3,7% in volume

Russia pharma market growth in January-February 2019

Source: IQVIA databases. Retail, Public, DLO, RLO (excluding food supplements and diagnostic agents), TRD Prices

151816

114

129

12

M02/YTD’19

149

M02/YTD’18

179

149

+20%

Retail

Public (EXCL. DLO AND RLO)

Reimbursement

Regional Reimbursement

0.7 0.7

M02/YTD’19

0,1

M02/YTD’18

0,1

0,8 0,8

+3,7%

VALUE, BLN RUB VOLUME, BLN PACKS

+25%

+108%

+14%

+14%

+31%

+6,7%

+3,8%

-2,6%

2

Retail Sell-Out: Market grew by 4,7% in value and deceased by 4,1% in volume

Russia pharma market growth in January-February 2019

Source: Pharmatrend (excluding food supplements and diagnostic agents), FIN Prices

VALUE, BLN RUB

YoY growth, % YoY growth, %

VOLUME, BLN PACKS

53%

47%

M02/YTD’18

51%

M02/YTD’19

49%

147154

+4,7%

RXOTC

66%

M02/YTD’18

68%

32%

M02/YTD’19

34%

0,760,73

-4,1%

+0,6%

+9,2%

-7,1%

+2,2%

3

Volume, mln packs

Sell-In vs Sell-Out, OTC registered drugs

Source: Retail Audit and Pharmatrend. OTC registered drugs

190

240

200

150

270

160

280

170

230

180

210

300

220

250

290

260

2018/09

255

240244243

2018/02

292

283

227

2018/03

246

2018/04 2018/05

237

225

216

2018/06

238

222

207

208

2018/07

226

221

2018/08

243

2018/10

241

248242

238

2018/12

225

253

2018/11

254

246

2019/01 2019/02

Sell-In Sell-Out

Mln

pa

ck

s

4

TOP-15 corporations on Russian market, January-February 2019

2,5%

MENARINI

PFIZER

SERVIER

Total pharma market

TAKEDA

SANOFI-AVENTIS

TEVA

SANDOZ

BAYER HEALTHCARE

JOHNSON & JOHNSON

2,3%NOVARTIS

3,9%

OTCPHARM

KRKA

GLAXOSMITHKLINE 2,1%

GEDEON RICHTER

100,0%

4,8%

2,6%

2,5%

2,4%

2,2%

2,1%

2,0%

2,0%

1,9%

1,8%

ABBOTT

2,3%

27%

45%

20%

15%

11%

8%

-3%

14%

9%

13%

12%

29%

7%

10%

18%

6%

-6%

4%

6%

8%

-2%

-8%

-2%

-1%

-9%

8%

14%

1%

15%

2%

3%

7%

Value growth / declineIn percent in Local Currency

Volume growth / declineIn percent in Packs

1

2

3

4

5

6

7

8

9

10

11

12

13

14

Market share, M02/YTD’19In percent in Local Currency

15


5

TOP-15 brands on Russian market, January-February 2019

ACTOVEGIN

REVLIMIDE

0,8%

SOLIRIS

XARELTO

NATRIUM CHLORIDUM

KAGOCEL

INGAVIRIN

0,5%

TOUJEO SOLOSTAR

OCTANATE

0,5%

ADVATE

ELAPRASE

Total pharma market

DETRALEX

MEXIDOL

MIRAMISTIN

KEYTRUDA

100,0%

0,7%

0,7%

0,7%

0,6%

0,5%

0,4%

0,4%

0,4%

0,4%

0,4%

0,4%

1,1%

2%

47%

20%

96%

70%

296%

14%

45%

94%

1 903%

1 770%

78%

12%

16%

4%

801%

305%

-4%

39%

101%

4%

14%

38%

88%

76%

1 511%

1 116%

1%

14%

0%

4%

1 181%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15





6

Plans of purchases – new offering launched in Q2 2019

7

Manufacturer

DistributorProcurement

announce-

ment

Documents

Customers must publish Plans of purchases, positions which are not included into Plans can not be bought

Goods flow

Customer

(Ministry,

hospital

etc)

Patients

Hospital

Scheduled

plans of

Procurement

Publication

of the

Contract

TendersPlans of

Purchases

Tenders.

Contracts

New!

Modules, provided by IQVIA

Zakupki.gov.ru

8

Plans of purchases, relevant facts

Frequency DAP Granularity Panel/Universe Back Data

Weekly 2018www.zakupki.gov.ruNational

RegionalMunicipal

2 days

Methodology

Granularity

Delivery tools

Published Plans of Drug Procurement.

The data is based on information on published tenders at

www.zakupki.gov.ru

Without extrapolation. Volumes are in primary published units. Classification by

Customers, molecules and release forms.

National level + 83 regions + Account Level data

▪ Online IQVIA Tool

▪ Customized E-Mail newsletters

Key indicators

Market Definition

9

IQVIA is launching Plans of Purchases offering that could beapplied for immediate monitoring and medium-term planning

Rating of Federal Districts by bublished plans of

purchases for 2019, as per current version of plans

TOP5 molecules to be purchased in 2019 as per current

versions of plans

TOP5 molecules by volumes to be announced

in 2Q’19 as per current versions of plans

TOP5 EphMRA-2 categoris by volumes to be

announced in 2019 as per current versions of

plans

1 2

3 4

6,2

3,3

5,8

5,0

4,3

LOPINAVIR*RITONAVIR

LENALIDOMIDE

VACCINE, PNEUMOCOCCAL

ECULIZUMAB

RALTEGRAVIR

Bln

rub

3,1

1,6

2,2

1,61,4

LOPINAVIR*RITONAVIR

RALTEGRAVIR

RITUXIMAB

ECULIZUMAB

TERIFLUNOMIDE

61.8%7.2%

6.6%

7,5%

4,2%

5,1%2,5%

5,0%

Central

Volga

Northwestern

Far Eastern

Siberian

Southern

Ural

North Caucasus

Bln

rub

Bln

rub

10,0

48,2

24,0

11,68,9 L04 IMMUNOSUPPRESSIVE AGENTS

L01 ANTINEOPLASTICS

J05 ANTIVIRALS FOR SYSTEMIC USE

J07 VACCINES

B02 ANTIFIBRINOLYTICS, ANTIDOTES TO ANTI-COAGULANTS, INHIBITORS, BLOOD COAGULATION AND HAEMOSTYPTICSB

lnru

b

10

Advertisement cost, Growth Y-to-Y

TOP-10 products by growth in advertisement investments in January-February 2019

Total salesBln RUB

Sales, Growth Y-to-Y

1.000%

276%

1.000%

1.000%

1.000%

145%

117%

99%

83%

81%

SNUP

0,86

GRAMMIDIN

FESTAL

0,49

LONGIDAZA

DETRALEX

AQUADETRIM

DE NOL 0,35

BRONCHO MUNAL

ERGOFERON

MICROLAX 0,41

0,62

0,51

0,25

0,24

0,37

0,76

39%

31%

17%

30%

2%

14%

11%

0%

46%

18%

The rank in calculated among TOP-200 Brands by sales with advertising cost greater than 50 mln RUB

Source: IQVIA databases. Pharmatrend, Mediascope data, FIN Prices

11

TOP-10 products by decline in advertisement investments in January-February 2019

Total salesBln RUB

Sales, Growth Y-to-Y

-24%

-27%

-49%

-40%

-29%

-34%

-39%

-36%

-23%

-23%

0,23

1,17

0,31

0,74

DOCTOR MOM

NUROFEN

0,26HYLAK FORTE

PENTALGIN

NOVO PASSIT

COMPLIVIT

CODELAC

STREPSILS

PROSTAMOL UNO

DUSPATALIN

0,51

0,38

0,60

0,36

0,34

-7%

11%

-7%

-3%

11%

-15%

-23%

4%

0%

2%

Advertisement cost, Growth Y-to-Y

The rank in calculated among TOP-200 Brands by sales with advertising cost greater than 50 mln RUB

Source: IQVIA databases. Pharmatrend, Mediascope data, FIN Prices

12

Indicator KZT USD EUR PACKS

Value M02/YTD’19, Bln. 71 0,19 0,16 0,10

Growth M02/YTD’19% 8,5% -7,3% 0,3% -3,4%

Market grew by 8,5% in value and decreased by 3,4% in volume

Kazakhstan pharma market growth in January-February 2019

Source: IQVIA databases. Retail, Hospital (excluding food supplements and diagnostic agents), TRD Prices

8

52

M02/YTD’18

44

11

11

71

11

M02/YTD’19

65

+8,5%

Retail

Hospital

Free & Co-Payment

M02/YTD’18

0,09

0,010,01

0,09

M02/YTD’19

0,10 0,10

-3,4%

VALUE, BLN KZT VOLUME, BLN PACKS

-0,8%

+18%

-20%

-8,5%

-0,4%

-26%

13

TOP-15 corporations on Kazakhstan market, January-February 2019

GEDEON RICHTER

NOBEL-AFF

2,5%

Total pharma market

SANOFI-AVENTIS

BAYER HEALTHCARE

TEVA

1,9%

2,5%

ABBOTT

TAKEDA

SANDOZ GROUP

GLAXOSMITHKLINE

3,6%

SERVIER

MENARINI

WORLD MEDICINE

ABDI IBR.GLOBAL PH

100,0%

6,9%

4,8%

4,0%

3,0%

2,9%

2,8%

2,2%

2,7%

2,6%

2,3%

2,2%

SANTO

JOHNSON & JOHNSON

-3%

3%

4%

25%

17%

9%

12%

-13%

-18%

34%

-8%

22%

8%

23%

17%

35%

-3%

12%

2%

-3%

-4%

19%

-13%

-20%

2%

2%

10%

-1%

-4%

-20%

16%

-15%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15





14

TOP-15 brands on Kazakhstan market, January-February 2019

IMMUTIN

ACTOVEGIN

Total pharma market

AVASTIN

THERAFLU

VIFERON

CEFAZOLIN

CANEPHRON N

PHYSIOTENZ

0,6%

SPIRITUS AETHYLIC 0,6%

0,6%

1,1%

NIMESIL

0,5%

IMMUNATE

0,7%

HYLAK FORTE

CORONIM 10

100,0%

0,7%

0,6%

0,6%

0,5%

0,6%

0,5%

0,5%

0,5%

GORDOX

MUCALTIN

0,5%

6%

27%

9%

4%

-4%

54%

51%

16%

7%

16%

126%

16%

65%

30%

2%

-8%

-12%

-3%

51%

12%

-1%

18%

-1%

158%

-14%

8%

20%

-13%

-2%

13%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15





15

Indicator BLR USD EUR PACKS

Value M02/YTD’19, Bln. 0,33 0,15 0,13 0,06

Growth M02/YTD’19% 8,0% -0,8% 6,8% 1,4%


Belarus pharma market growth in January-February 2019

0,07

M02/YTD’18

0,24

0,06

M02/YTD’19

0,26

0,300,33

+8,0%

Retail

Hospital

0,01 0,01

0,05

M02/YTD’19M02/YTD’18

0,05

0,06 0,06

+1,4%

VALUE, BLN BLR VOLUME, BLN PACKS

+6,6%

+14%

+0,4%

+6,9%


16

TOP-15 corporations on Belarus market, January-February 2019

3,1%

3,8%

Total pharma market

SANOFI

BORISOV ZMP

BELMEDPREPARATY RUE

LEKPHARM JLLC

NOVARTIS

KRKA

PHARMLAND JV LTD

2,4%

PHARMTECHNOLOGY LTD

BAYER HEALTHCARE

MINSKINTERCAPS MRUE

GEDEON RICHTER

GSK

OLAINFARM AS

100,0%

7,6%

7,5%

5,3%

4,0%

3,7%

3,1%

2,6%

2,5%

2,0%

1,9%

1,9%

1,6%

BERLIN-CH/MENARINI

TAKEDA

30%

7%

-26%

8%

-9%

15%

67%

4%

18%

14%

30%

22%

-2%

-4%

14%

19%

-6%

-2%

27%

37%

1%

-4%

12%

12%

2%

4%

11%

6%

-6%

-1%

12%

-21%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15





17

TOP-15 brands on Belarus market, January-February 2019

0,8%

Total pharma market

IMOVAX POLIO

DACLASOFT 0,7%

CEREPRO

METFORMIN

T-MAB

GLICLAZIDE MR

0,5%

1,0%

LISINOPRIL

ATORVASTATIN

BERIATE

0,5%

ACTOVEGIN

LOSARTAN

GROPRINOSIN

100,0%

1,0%

0,7%

0,7%

0,6%

0,5%

0,6%

0,5%

0,5%

0,5%

0,5%

SODIUM CHLORIDE

XARELTO

FLUSTOP

23%

119%

2 856%

302%

8%

9%

10 499%

57%

9%

4%

301%

29%

13%

7%

13%

308%

1%

53%

301%

8%

2 736%

7%

2 484%

5%

-4%

125%

9%

34%

13%

16%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15





18

Indicator AMD USD EUR PACKS

Value M02/YTD’19, Bln. 13,2 0,03 0,02 0,01

Growth M02/YTD’19% 5,2% 4,2% 12% 0,7%

Market grew by 5,2% in value and by 0,7% in volume

Armenia pharma market growth in January-February 2019

Source: IQVIA databases. Retail Market (exclude food supplements and diagnostic agents), TRD Prices

M02/YTD’18 M02/YTD’19

13,212,5

+5,2%

Retail

M02/YTD’18 M02/YTD’19

0,01 0,01

+0,7%

VALUE, BLN AMD VOLUME, BLN PACKS

19

TOP-15 corporations on Armenia market, January-February 2019


2,0%

Total pharma market

BERLIN-CH/MENARINI

SERVIER

100,0%

NOVARTIS

GSK

KRKA

SANOFI

TAKEDA

GEDEON RICHTER

EGIS

DENK PHARMA

BAYER HEALTHCARE 2,4%

ABBOTT

GL CORPORATION

6,4%

5,7%

4,3%

3,8%

3,0%

3,7%

3,3%

3,1%

3,0%

1,8%

2,7%

2,2%

2,0%ASTELLAS PHARMA

STADA

5%

27%

6%

-1%

7%

-3%

-6%

3%

-6%

4%

-3%

-5%

13%

12%

-14%

-14%

1%

-4%

13%

-2%

1%

-1%

-4%

-10%

-3%

0%

-9%

-8%

6%

11%

-16%

-17%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15




20

TOP-15 brands on Armenia market, January-February 2019


Total pharma market

PRESTANCE

CARDIOMAGNYL

CONCOR

ACTOVEGIN

DUPHASTON

0,4%

CEFTRIAXONE-ASTERIA

NIMESIL

0,7%

LENDACIN

0,6%

THERAFLU

SODIUM CHLORIDE

1,0%

0,5%

VITAMIN D3

DEXALGIN SACHET

100,0%

0,9%

0,8%

0,7%

0,6%

0,5%

0,5%

0,5%

0,4%

0,5%

0,4%

XARELTO

TRIPLIXAM

OTRIVIN

5%

1%

21%

16%

4%

-17%

-15%

7%

-22%

-18%

-14%

0%

57%

56%

0%

19%

-12%

1%

23%

-25%

16%

12%

-8%

1%

-24%

-21%

-14%

1%

-2%

49%

34%

11%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15




21

Indicator GEL USD EUR PACKS

Value M02/YTD’19, Bln. 0,11 0,04 0,04 0,02

Growth M02/YTD’19% 7,8% 1,5% 10% 10%

Market grew by 7,8% in value and by 10% in volume

Georgia pharma market growth in January-February 2019


M02/YTD’19M02/YTD’18

0,100,11

+7,8%

Retail

M02/YTD’18

0,02

M02/YTD’19

0,02

+10%

VALUE, BLN GEL VOLUME, BLN PACKS

22

TOP-15 corporations on Georgia market, January-February 2019


G.M.P. LTD

1,5%

Total pharma market

1,6%

BERLIN-CH/MENARINI

4,4%

WORLD MEDICINE

AVERSI-RATIONAL LTD

GSK

3,1%

SANOFI

SERVIER

KRKA

BAYER HEALTHCARE

NOVARTIS

5,5%

ASTRAZENECA

ROCHE

TAKEDA

EGIS

GEDEON RICHTER

100,0%

5,4%

4,5%

3,8%

2,3%

2,9%

3,6%

1,7%

3,5%

2,1%

1,5%

-23%

8%

22%

13%

10%

38%

1%

-8%

-11%

6%

15%

5%

-3%

7%

13%

1%

4%

37%

9%

10%

3%

11%

-3%

-10%

-1%

3%

9%

17%

0%

6%

11%

-5%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15




23

TOP-15 brands on Georgia market, January-February 2019


0,6%

0,7%

XARELTO

Total pharma market

CARDIOMAGNYL

NIMESIL

0,5%

TRIPLIXAM

NO-SPA

PRESTANCE

0,4%

SODIUM CHLORIDE 0,6%

THERAFLU

AUGMENTIN

CORSIZ

CEFAMED

PULMICORT

FRAXIPARINE

CLEXANE

0,4%

100,0%

1,0%

0,8%

0,7%

0,7%

0,5%

0,7%

0,4%

0,4%

0,7%

DETRALEX

34%

8%

-12%

0%

23%

-4%

-9%

12%

6%

37%

194%

6%

92%

-18%

3%

27%

-9%

4%

37%

10%

10%

-1%

19%

34%

28%

15%

199%

5%

57%

-10%

-1%

3%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15




24

Indicator AZN USD EUR PACKS

Value M02/YTD’19, Bln. 0,12 0,07 0,06 0,04

Growth M02/YTD’19, % 12% 12% 21% 5,2%


Azerbaijan pharma market growth in January-February 2019


M02/YTD’18 M02/YTD’19

0,120,11

+12%

Retail

0,04

M02/YTD’18 M02/YTD’19

0,04

+5,2%

VALUE, BLN AZN VOLUME, BLN PACKS

25

TOP-15 corporations on Azerbaijan market, January-February 2019


2,9%

KRKA

BERLIN-CH/MENARINI

Total pharma market

NOVATOR PHARMA

GSK

NOVARTIS

1,3%

STADA

TAKEDA

SERVIER

NOBEL ILAC SANAYII

BORISOV ZMP

VEFA ILAC SANAYI

1,8%

EGIS

HERBA FLORA

MARATHON PHARMA

100,0%

2,2%

3,7%

3,4%

2,8%

2,4%

1,9%

1,8%

1,6%

1,6%

1,3%

1,2%

SANOFI

1,7%

0%

12%

39%

5%

0%

19%

-5%

-4%

-2%

9%

13%

43%

3%

22%

11%

-17%

-19%

41%

-2%

2%

5%

-15%

-6%

-1%

11%

17%

-1%

21%

5%

14%

2%

-18%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15




26

TOP-15 brands on Azerbaijan market, January-February 2019


NIMESIL

ACTOVEGIN

SODIUM CHLORIDE

0,6%

SPASMALGON

NUROFEN FOR CHILD

AUGMENTIN

ETHANOL 0,6%

CLEXANE

RINGER`S SOLUTION

CEFTRIAXONE-AKOS

0,6%

TYLOL HOT

0,5%

CARDIOMAGNYL

0,8%

TRIPLIXAM

ALBUNORM

100,0%

1,3%

0,5%

0,6%

0,8%

0,7%

0,7%

0,5%

0,5%

0,4%

0,4%

Total pharma market

TRIOCEF

0%

6%

12%

-6%

59%

104%

11%

35%

-12%

68%

26%

-26%

9%

43%

955%

26%

-5%

7%

59%

5%

33%

-16%

-6%

7%

26%

71%

75%

26%

-26%

6%

54%

575%

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15




27

Please Contact Us for More Information

Svetlana Nikulina

Sales Director

[email protected]

+7 499 272 05 00

Anton Kalyapin

Associate Director, Offering

[email protected]

+7 499 272 05 00

Nadezhda Kalinich

Client Service Representative

[email protected]

+7 499 272 05 00

mailto:[email protected]

